Semi-annual report_Semi-annual report_Joincare Pharmaceutical Group Industry Co., Ltd.

简体中文 | English



Investor Relations

Listed on the Shanghai Stock Exchange in June 2001, with a maximum market value of 47.5 billion



Your location：

Homepage

Investor Relations

Semi-annual report

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Resolutions of 2023 Sencond Extraordinary General Meeting

Categories:

Announcement

Time:

2023-09-15 17:30:00
Ad hoc announcement pursuant to Art-JCARE Announcement on the Acceptance of the Application for Marketing Authorization for Aripiprazole Microspheres for Injection

Categories:

Announcement

Time:

2023-09-12 18:00:00
Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Appointment of Vice President of The Company

Categories:

Announcement

Time:

2023-09-08 18:30:00
Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on the Acceptance of the Application for Marketing Authorization for the New Indication of Triptorelin Acetate Microspheres for Injection

Categories:

Announcement

Time:

2023-08-24 17:50:00
Ad hoc announcement pursuant to Art. 53 LR-JCARE Notice of 2023 Second Extraordinary General Meeting

Categories:

Announcement

Time:

2023-08-23 18:00:00
Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Resignation of Independent Director and By-election of Independent Director

Categories:

Announcement

Time:

2023-08-23 18:00:00
Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Approval for Registration of Blonanserin Tablets

Categories:

Announcement

Time:

2023-08-11 18:00:00
Ad hoc announcement pursuant to Art. 53 LR-JCARE Supplemental Announcement on the Livzon Group Entering into the Patent and Technology Transfer Agreement

Categories:

Announcement

Time:

2023-07-21 18:15:00
Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on the Livzon Group Entering into The Patent and Technology Transfer Agreement

Categories:

Announcement

Time:

2023-07-20 17:30:00
Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Obtaining the Approval of Drug Clinical Trials for Recombinant SARS-COV-2 Bivalent (Original/Omicron XBB) Fusion Protein Vaccine (CHO Cell)

Categories:

Announcement

Time:

2023-07-14 17:00:00

Page up

...

Page down

Quick Navigation

Product

Online Mall

0755-33268688

Service Hotline

Quick

Navigation

Service

Hotline

0755-33268688

Joincare Pharmaceutical Group Industry Co., Ltd.

Official WeChat Official Account

Corporate Governance

Subscribe

Investor Service

Financial reports

Corporate Calendar

GDR release information

Corporate Governance

Subscribe

Investor Service

Financial reports

Corporate Calendar

GDR release information

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Resolutions of 2023 Sencond Extraordinary General Meeting

Ad hoc announcement pursuant to Art-JCARE Announcement on the Acceptance of the Application for Marketing Authorization for Aripiprazole Microspheres for Injection

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Appointment of Vice President of The Company

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on the Acceptance of the Application for Marketing Authorization for the New Indication of Triptorelin Acetate Microspheres for Injection

Ad hoc announcement pursuant to Art. 53 LR-JCARE Notice of 2023 Second Extraordinary General Meeting

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Resignation of Independent Director and By-election of Independent Director

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Approval for Registration of Blonanserin Tablets

Ad hoc announcement pursuant to Art. 53 LR-JCARE Supplemental Announcement on the Livzon Group Entering into the Patent and Technology Transfer Agreement

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on the Livzon Group Entering into The Patent and Technology Transfer Agreement

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Obtaining the Approval of Drug Clinical Trials for Recombinant SARS-COV-2 Bivalent (Original/Omicron XBB) Fusion Protein Vaccine (CHO Cell)